Metabolic complications of HIV therapy in children

AIDS

Volumn 18, Issue 13, 2004, Pages 1753-1768

  McComsey, Grace A ^a,b   Leonard, Ethan ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hyperlactatemia; Insulin resistance; Lipoatrophy; Lipodystrophy; Mitochondrial toxicity; Osteopenia

Indexed keywords

ANTIRETROVIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

AVASCULAR NECROSIS; BONE DISEASE; BONE MINERAL; CARDIOVASCULAR DISEASE; DYSLIPIDEMIA; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LIPOATROPHY; LIPODYSTROPHY; LIPOHYPERTROPHY; METABOLIC DISORDER; MITOCHONDRIAL TOXICITY; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BONE DISEASES; CARDIOVASCULAR DISEASES; CHILD; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; HYPERLIPIDEMIAS; INSULIN RESISTANCE; MITOCHONDRIAL DISEASES;

EID: 4444315072     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200409030-00004     Document Type: Review

References (197)

1. Palella FJ, Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860.
2. Leonard EG, McComsey GA. Metabolic complications of antiretroviral therapy in children. Pediatr Infect Dis J 2003, 22:77-84.
3. Amaya R, Kozinetz C, McMeans A, Schwarzwald H, Kline M. Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2002, 21:405-410.
4. Arpadi SM, Cuff PA, Horlick M, Wang J, Kotler DP. Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+ lymphocyte count and CD4+ lymphocyte percentage at baseline and use of protease inhibitors and stavudine. J Acquir Immune Defic Syndr 2001, 27:30-34.
5. Bitnun A, Sochett E, Babyn P, Holowka S, Stephens D, Read S, et al. Serum lipids, glucose homeostasis and abdominal adipose tissue distribution in protease inhibitor-treated and naive HIV-infected children. AIDS 2003, 17:1319-1327.
6. Bockhorst JL, Ksseiry I, Toye M, Chipkin SR, Stechenberg BW, Fisher DJ, et al. Evidence of human immunodeficiency virus-associated lipodystrophy syndrome in children treated with protease inhibitors. Pediatr Infect Dis J 2003, 22:463-465.
7. Brambilla P, Bricalli D, Sala N, Renzetti F, Manzoni P, Vanzulli A, et al. Highly active antiretroviral-treated HIV-infected children show fat distribution changes even in absence of lipodystrophy. AIDS 2001, 15:2415-2422.
8. Cheseaux JJ, Jotterand V, Aebi C, Gnehm H, Kind C, Nadal D, et al. Hyperlipidemia in HIV-infected children treated with protease inhibitors: relevance for cardiovascular diseases. J Acquir Immune Defic Syndr 2002, 30:288-293.
9. Farley J, Gona P, Crain M, Cervia J, Lindsey J, Oleske J. Prevalence of hypercholesterolemia and associated risk factors among perinatally HIV-infected children (4-19 years) in PACTG 219C. Tenth Conference on Retroviruses and Opportunistic Infections. Boston, February 2003 [abstract 773].
10. Jaquet D, Levine M, Ortega-Rodriguez E, Faye A, Polak M, Vilmer E, et al. Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS 2000, 14:2123-2128.
11. Melvin AJ, Lennon S, Mohan KM, Purnell JQ. Metabolic abnormalities in HIV type 1-infected children treated and not treated with protease inhibitors. AIDS Res Hum Retroviruses 2001, 17:1117-1123.
12. Ramos J, Garcia L, Rojo P, Ruano C, Careno P, Ruiz-Contreras J, et al. High prevalence of metabolic abnormalities in HIV infected children treated with HAART. Tenth Conference on Retroviruses and Opportunistic Infections. Boston, February 2003 [abstract 772].
13. Vigano A, Mora S, Testolin C, Beccio S, Schneider L, Bricalli D, et al. Increased lipodystrophy is associated with increased exposure to highly active antiretroviral therapy in HIV-infected children. J Acquir Immune Defic Syndr 2003, 32:482-489.
14. Vink NM, van Rossum AM, Hartwig NG, de Groot R, Geelen S. Lipid and glucose metabolism in HIV-1-infected children treated with protease inhibitors. Arch Dis Child 2002, 86:67.
15. Thiebaut R, Daucourt V, Mercie P, Ekouevi DK, Malvy D, Morlat P, et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidemiologie Clinique du Syndrome d'Immunodeficience Acquise en Aquitaine. Clin Infect Dis 2000, 31:1482-1487.
16. Kingsley L, Smit E, Riddler S. Prevalence of lipodystrophy and metabolic abnormalities in the Multicenter AIDS Cohort Study (MACS). Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [abstract 538].
17. Saint-Marc T, Partisani M, Poizot-Martin I, Bruno F, Rouviere O, Lang JM, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999, 13:1659-1667.
18. Seidell JC, Bakker CJ, van der Kooy K. Imaging techniques for measuring adipose-tissue distribution: a comparison between computed tomography and 1.5-T magnetic resonance. Am J Clin Nutr 1990, 51:953-957.
19. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998, 351:871-875.
20. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996, 334:952-957.
21. Manson JE, Colditz GA, Stampfer MJ, Willett WC, Rosner B, Monson RR, et al. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med 1990, 322:882-889.
22. Larsson B, Svardsudd K, Welin L, Wilhelmsen L, Bjorntorp P, Tibblin G. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. Br Med J (Clin Res Ed) 1984, 288:1401-1404.
23. Howard G, Bergman R, Wagenknecht LE, Haffner SM, Savage PJ, Saad MF, et al. Ability of alternative indices of insulin sensitivity to predict cardiovascular risk: comparison with the 'minimal model'. Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Ann Epidemiol 1998, 8:358-369.
24. Haffner SM, Kennedy E, Gonzalez C, Stern MP, Miettinen H. A prospective analysis of the HOMA model. The Mexico City Diabetes Study. Diabetes Care 1996, 19:1138-1141.
25. Meigs JB, Nathan DM, Wilson PW, Cupples LA, Singer DE. Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance. The Framingham Offspring Study. Ann Intern Med 1998, 128:524-533.
26. Walton C, Lees B, Crook D, Worthington M, Godsland IF, Stevenson JC. Body fat distribution, rather than overall adiposity, influences serum lipids and lipoproteins in healthy men independently of age. Am J Med 1995, 99:459-464.
27. Meigs JB, D'Agostino RB, Sr., Wilson PW, Cupples LA, Nathan DM, Singer DE. Risk variable clustering in the insulin resistance syndrome. The Framingham Offspring Study. Diabetes 1997, 46:1594-1600.
28. D'Agostino RB, Sr., Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001, 286:180-187.
29. Hadigan C, Meigs JB, Wilson PW, D'Agostino RB, Davis B, Basgoz N, et al. Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clin Infect Dis 2003, 36:909-916.
30. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families. The Framingham Offspring Study. Am J Epidemiol 1979, 110:281-290.
31. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003, 348:702-710.
32. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003, 349:1993-2003.
33. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio Monforte A, et al. Cardiovascular disease risk factors in HIV patients: association with antiretroviral therapy. Results from the DAD study. AIDS 2003, 17:1179-1193.
34. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003, 17:2479-2486.
35. Duran S, Saves M, Spire B, Cailleton V, Sobel A, Carried P, et al. Failure to maintain long-term adherence to highly active anti-retroviral therapy: the role of lipodystrophy. AIDS 2001, 15:2441-2444.
36. Dukers NH, Stolte IG, Albrecht N, Coutinho RA, de Wit JB. The impact of experiencing lipodystrophy on the sexual behaviour and well-being among HIV-infected homosexual men. AIDS 2001, 15:812-813.
37. Wedekind CA, Pugatch D. Lipodystrophy syndrome in children infected with human immunodeficiency virus. Pharmacotherapy 2001, 21:861-866.
38. Mulligan K, Baldwin C, Langroudi B, Mandalia S, Gazzard BG. Trunk fat is conserved with Pl-based HAART, but not with non-Pl based HAART, in HIV-infected women in the USA: DEXA sub-study in the Women's Interagency HIV Study Program. Fifth International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Paris, July 2003 [abstract 15].
39. Gripshover B, Tien PC, Saag M, Osmond D, Bacchetti P, Grunfeld C, et al. Lipoatrophy is the dominant feature of the lipodystrophy syndrome in HIV-infected men. Tenth Conference on Retroviruses and Opportunistic Infections. Boston, February 2003 [abstract 732].
40. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-F58.
41. Galli M, Ridolfo AL, Adorni F, Gervasoni C, Ravasio L, Corsico L, et al. Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2002, 29:21-31.
42. Mallal SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000, 14:1309-1316.
43. Cohen C, Shen Y, Rode R, Cameron DW, Mellors J, Farthing C, et al. Effect of nucleoside intensification on prevalence of morphologic abnormalities at year 5 of ritonavir plus saquinavir therapy in an HIV-infected cohort. Ninth Conference on Retroviruses and Opportunistic Infections. Seattle, February 2002 [abstract 683-T].
44. van der Valk M, Gisolf EH, Reiss P, Wit FW, Japour A, Weverling GJ, et al. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS 2001, 15:847-855.
45. Galli M, Ridolfo AL, Adorni F, Cappelletti A, Morelli P, Massetto B, et al. Correlates of risk of adipose tissue alterations and their modifications over time in HIV-1-infected women treated with antiretroviral therapy. Antivir Ther 2003, 8:347-354.
46. Joly V, Flandre P, Meiffredy V, Leturque N, Harel M, Aboulker JP, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 2002, 16:2447-2454.
47. Podzamczer D, Ferrer E, Sanchez P, Gatell J, Crespo M, Lonca M, et al. Toxicity and efficacy of 3TC/EFV associated with stavudine or abacavir in antiretroviral-naive patients: 48 week results of a randomized open and multicenter trial (ABCDE) study. Eleventh Conference on Retroviruses and Opportunistic Infections. San Francisco, February 2004 [abstract 716].
48. Chene G, Angelini E, Cotte L, Lang JM, Morlat P, Rancinan C, et al. Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. Clin Infect Dis 2002, 34:649-657.
49. Amin J, Moore A, Carr A, French MA, Law M, Emery S, et al. Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: OzCombo 1 and 2. HIV Clin Trials 2003, 4:252-261.
50. McComsey G, Bhumbra N, Ma JF, Rathore M, Alvarez A. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study. Pediatrics 2003, 111:e275-e281.
51. Martinez E, Garcia-Viejo MA, Blanco JL, Bianchi L, Buira E, Conget I, et al. Impact of switching from human immuno-deficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. Clin Infect Dis 2000, 31:1266-1273.
52. Moyle GJ, Baldwin C, Langroudi B, Mandalia S, Gazzard BG. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr 2003, 33:22-28.
53. Ruiz L, Negredo E, Domingo P, Paredes R, Francia E, Balague M, et al. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. J Acquir Immune Defic Syndr 2001, 27:229-236.
54. Boyd M, Bien D, Van Warmerdam P, Hassink E, Srasuebkul P, Chomchey N, et al. Lipodystrophy in patients switched to indinavir/ritonavir 800/100 mg BID and efavirenz 600 mg QD after failing nucleoside combination therapy: a prospective, 48-week observational sub-study of HIV-NAT. Tenth Conference on Retroviruses and Opportunistic Infections. Boston, February 2003 [abstract 009].
55. McComsey GA, Ward DJ, Hessenthaler SM, Sension MG, Shalit P, Lonergan JT, et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis 2004, 38:263-270.
56. Carr A, Workman C, Smith D, Hoy J, Hudson J, Doong N, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 2002, 288:207-215.
57. Lichtenstein KA, Ward DJ, Moorman AC, Delaney KM, Young B, Palella FJ, Jr, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001, 15:1389-1398.
58. Heath KV, Hogg RS, Singer J, Chan KJ, O'Shaughnessy MV, Montaner JS. Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based chort. J Acquir Immune Defic Syndr 2002, 30:440-447.
59. McComsey G, Maa JF. Host factors may be more important than choice of antiretrovirals in the development of lipoatrophy. AIDS Read 2003, 13:539-542, 559.
60. Brunton JA, Bayley HS, Atkinson SA. Validation and application of dual-energy X-ray absorptiometry to measure bone mass and body composition in small infants. Am J Clin Nutr 1993, 58:839-845.
61. Ellis KJ, Shypailo RJ, Pratt JA, Pond WG. Accuracy of dual-energy X-ray absorptiometry for body-composition measurements in children. Am J Clin Nutr 1994, 60:660-665.
62. Brambilla P, Manzoni P, Sironi S, Simone P, Del Maschio A, di Natale B, et al. Peripheral and abdominal adiposity in childhood obesity. Int J Obes Relat Metab Disord 1994, 18:795-800.
63. Berenson GS, Srinivasan SR, Bao W, Newman WP, III, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 1998, 338:1650-1656.
64. Goran MI, Gower BA. Relation between visceral fat and disease risk in children and adolescents. Am J Clin Nutr 1999, 70:149S-156S.
65. Steinberger J, Daniels SR. Obesity, insulin resistance, diabetes, and cardiovascular risk in children: an American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). Circulation 2003, 107:1448-1453.
66. McComsey GA, Morrow JD. Lipid oxidative markers are significantly increased in lipoatrophy, but not in sustained asymptomatic hyperlactatemia. J Acquir Immune Defic Syndr 2003, 34:45-49.
67. McComsey G, Southwell H, Gripshover B, Salata R, Valdez H. Effects of antioxidants on plasma lipids and peripheral fat in HIV-infected subjects with lipoatrophy. J Acquir Immune Defic Syndr 2003, 33:605-607.
68. Gelato MC, Mynarcik DC, Quick JL, Steigbigel RT, Fuhrer J, Brathwaite CE, et al. Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study. J Acquir Immune Defic Syndr 2002, 31:163-170.
69. Carr A, Workman C, Carey D, Rogers G, Martin A, Baker D, et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 2004, 363:429-438.
70. Sutinen J, Hakkinen AM, Westerbacka J, Seppala-Lindroos A, Vehkavaara S, Halavaara J, et al. Rosiglitazone in the treatment of HAART associated lipodystrophy: a randomized double-blind, placebo-controlled study. Antivir Ther 2003, 8:199-207.
71. Rietschel P, Hadigan C, Corcoran C, Stanley T, Neubauer G, Gertner J, et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metab 2001, 86:504-510.
72. Kotler DP, Grunfeld C, Muurahainen N, Wanke C, Thompson M, Bock D, et al. Low-dose mainenance therapy with recombinant human growth hormone sustains effects of previous r-hCH treatment in HIV+ patients with excess center fat: treatment results at 60 weeks. Eleventh Conference on Retroviruses and Opportunistic Infections. San Francisco, February 2004 [abstract 80].
73. Engelson ES, Glesby MJ, Mendez D, Albu JB, Wang J, Heymsfield SB, et al. Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J Acquir Immune Defic Syndr 2002, 30:379-391.
74. Vigano A, Mora S, Brambilla P, Schneider L, Merlo M, Monti LD, et al. Impaired growth hormone secretion correlates with visceral adiposity in highly active antiretroviral treated HIV-infected adolescents. AIDS 2003, 17:1435-1441.
75. Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pierson RN. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1969, 86:27-31.
76. Mulligan K, Grunfeld C, Tai VW, Algren H, Pang M, Chernoff DN, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000, 23:35-43.
77. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor- associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353:2093-2099.
78. Graham NM. Metabolic disorders among HIV-infected patients treated with protease inhibitors: a review. J Acquir Immune Defic Syndr 2000, 25(Suppl 1):S4-S11.
79. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med 2000, 160:2050-2056.
80. Walli R, Herfort O, Michl GM, Demant T Jager H, Dieterle C, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998, 12:F167-F173.
81. Wanke CA. Epidemiological and clinical aspects of the metabolic complications of HIV infection the fat redistribution syndrome. AIDS 1999, 13:1287-1293.
82. Henry K, Melroe H, Huebsch J, Hermundson J, Levine C, Swensen L, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998, 351:1328.
83. Noor MA, Grasela D, Parker R, Chaudhari U, Uderman H, Currie A, et al. The effect of atazanavir vs. lopinavir/ritonavir on insulin-stimulated glucose disposal in healthy subjects. Eleventh Conference on Retroviruses and Opportunistic Infections. San Francisco, February 2004 [abstract 702].
84. Purnell JQ, Zambon A, Knopp RH, Pizzuti DJ, Achari R, Leonard JM, et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000, 14:51-57.
85. National Center for Health Statistics, Center for Disease Control and Prevention. Third National Health and Nutrition Examination Survey. 1988-1994 (NHANES III). Hyattsville, MD: National Center for Health Statistics; 1999.
86. Babl FE, Regan AM, Pelton SI. Xanthomas and hyperlipidemia in a human immunodeficiency virus-infected child receivng highly active antiretroviral therapy. Pediatr Infect Dis J 2002, 21:259-260.
87. Mueller BU, Nelson RP, Jr, Sleasman J, Zuckerman J, Heath-Chiozzi M, Steinberg SM, et al. A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection. Pediatrics 1998, 101:335-343.
88. Funk MB, Linde R, Wintergerst U, Notheis G, Hoffmann F, Schuster T, et al. Preliminary experiences with triple therapy including nelfinavir and two reverse transcriptase inhibitors in previously untreated HIV-infected children. AIDS 1999, 13:1653-1658.
89. Depairon M, Chessex S, Sudre P, Rodondi N, Doser N, Chave JP, et al. Premature atherosclerosis in HIV-infected individuals: focus on protease inhibitor therapy. AIDS 2001, 15:329-334.
90. Mercie P, Thiebaut R, Lavignolle V, Pellegrin JL, Yvorra-Vives MC, Morlat P, et al. Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement. Ann Med 2002, 34:55-63.
91. Dubé MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003, 37:613-627.
92. The Expert Panel of the National Cholesterol Education Program. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001, 285:2486-2497.
93. Wierzbicki AS, Reynolds TM, Crook MA, Tatler J, Peters BS. Lipid lowering therapy in patients with HIV infection. Lancet 1998, 352:1782.
94. Penzak SR, Chuck SK. Management of protease inhibitor-associated hyperlipidemia. Am J Cardiovasc Drugs 2002, 2:91-106.
95. Stein EA, Illingworth DR, Kwiterovich PO, Jr, Liacouras CA, Siimes MA, Jacobson MS, et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA 1999, 281:137-144.
96. American Academy of Pediatrics. Committee on Nutrition. Cholesterol in childhood. Pediatrics 1998, 101:141-147.
97. Martinez E, Conget I, Lozano L, Casamitjana R, Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999, 13:805-810.
98. Negredo E, Ribalta J, Paredes R, Ferre R, Sirera G, Ruiz L, et al. Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS 2002, 16:1383-1389.
99. Food and Drug Administration Protease inhibitors may increase blood glucose in HIV patients. Washington, DC: Food and Drug Administration; 1997.
100. Anderson RL, Hamman RF, Savage PJ, Saad MF, Laws A, Kades WW, et al. Exploration of simple insulin sensitivity measures derived from frequently sampled intravenous glucose tolerance (FSIGT) tests. The Insulin Resistance Atherosclerosis Study. Am J Epidemiol 1995, 142:724-732.
101. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Korner T, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999, 13:F63-F70.
102. Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001, 32:130-139.
103. Hadigan C, Borgonha S, Rabe J, Young V, Grinspoon S. Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy. Metabolism 2002, 51:1143-1147.
104. Hadigan C, Corcoran C, Stanley T, Piecuch S, Klibanski A, Grinspoon S. Fasting hyperinsulinemia in human immunodeficiency virus-infected men: relationship to body composition, gonadal function, and protease inhibitor use. J Clin Endocrinol Metab 2000, 85:35-41.
105. Kosmiski LA, Kuritzkes DR, Lichtenstein KA, Glueck DH, Gourley PJ, Stamm ER, et al. Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome. AIDS 2001, 15:1993-2000.
106. Meininger G, Hadigan C, Rietschel P, Grinspoon S. Body-composition measurements as predictors of glucose and insulin abnormalities in HIV-positive men. Am J Clin Nutr 2002, 76:460-465.
107. Murata H, Hruz PW, Mueckler M. Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. AIDS 2002, 16:859-863.
108. Rudich A, Vanounou S, Riesenberg K, Porat M, Tirosh A, Harman-Boehm I, et al. The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3T3-L1 adipocytes. Diabetes 2001, 50:1425-1431.
109. Cook JS, Hoffman RP, Stene MA, Hansen JR Effects of maturational stage on insulin sensitivity during puberty. J Clin Endocrinol Metab 1993, 77:725-730.
110. Travers SH, Jeffers BW, Bloch CA, Hill JO, Eckel RH. Gender and Tanner stage differences in body composition and insulin sensitivity in early pubertal children. J Clin Endocrinol Metab 1995, 80:172-178.
111. Hadigan C, Jeste S, Anderson EJ, Tsay R, Cyr H, Grinspoon S. Modifiable dietary habits and their relation to metabolic abnormalities in men and women with human immunodeficiency virus infection and fat redistribution. Clin Infect Dis 2001, 33:710-717.
112. Thoni GJ, Fedou C, Brun JF, Fabre J, Renard E, Reynes J, et al. Reduction of fat accumulation and lipid disorders by individualized light aerobic training in human immunodeficiency virus infected patients with lipodystrophy and/or dyslipidemia. Diabetes Metab 2002, 28:397-404.
113. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA 2000, 284:472-477.
114. Hadigan C, Rabe J, Grinspoon S. Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2002, 87:4611-4615.
115. Saint-Marc T, Touraine JL. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy. AIDS 1999, 13:1000-1002.
116. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998, 338:867-872.
117. Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, et al. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998, 128:176-185.
118. Drechsler H, Powderly WG. Switching effective antiretroviral therapy: a review. Clin Infect Dis 2002, 35:1219-1230.
119. Mosekilde L. Sex differences in age-related loss of vertebral trabecular bone mass and structure: biomechanical consequences. Bone 1989, 10:425-432.
120. Hoy J, Hudson J, Law M, Cooper D. Osteopenia in a randomized multicentre study of protease inhibitor substitution in patients with lipodystrophy syndrome and well-controlled HIV viraemia: extended follow-up to 48 weeks. Second International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Toronto, September 2000 [abstract P32].
121. Carr A, Miller J, Eisman JA, Cooper DA. Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS 2001, 15:703-709.
122. Huang JS, Rietschel P, Hadigan CM, Rosenthal DI, Grinspoon S. Increased abdominal visceral fat is associated with reduced bone density in HIV-infected men with lipodystrophy. AIDS 2001, 15:975-982.
123. Tebas P, Powderly WG, Claxton S, Marin D, Tantisirivvat W, Teitelbaum SL, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000, 14:F63-F67.
124. McComsey G, Huang J, Wooley I, Young B, Sax P, Gerber M, et al. Fragility fractures in HIV-infected subjects: an area for improvement. Eleventh Conference on Retroviruses and Opportunistic Infections. San Francisco, February 2004 [abstract 743].
125. Guaraldi G, Ventura P, Albuzza M, Orlando G, Bedini A, Amorico G, et al. Pathological fractures in AIDS patients with osteopenia and osteoporosis induced by antiretroviral therapy. AIDS 2001, 15:137-138.
126. Stephens EA, Das R, Madge S, Barter J, Johnson MA. Symptomatic osteoporosis in two young HIV-positive African women. AIDS 1999, 13:2605-2606.
127. Schwarzwald H, Ellis KJ, Evans D, Kline N, McMeans A, Kline M. Effect of HAART on bone density in HIV-infected children. Tenth Conference on Retroviruses and Opportunistic Infections. Boston, February 2003 [abstract 778].
128. McComsey G, Leonard E. The effect of calcium and vitamin D on bone mineral density in HIV-infected children with osteoporosis. Tenth Conference on Retroviruses and Opportunistic Infections. Boston, February 2003 [abstract 779].
129. Mora S, Sala N, Bricalli D, Zuin G, Chiumello G, Vigano A. Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy. AIDS 2001, 15:1823-1829.
130. Mora S, Zamproni I, Beccio S, Bianchi R, Giacomet V, Vigano A. Longitudinal changes of bone mineral density and metabolism in antiretroviral-treated human immunodeficiency virus-infected children. J Clin Endocrinol Metab 2004, 89:24-28.
131. Tan BM, Nelson RP, Jr, James-Yarish M, Emmanuel PJ, Schurman SJ. Bone metabolism in children with human immunodeficiency virus infection receiving highly active anti-retroviral therapy including a protease inhibitor. J Pediatr 2001, 139:447-451.
132. Arpadi S, Horlick M, Verret W, Cuff P, Thornton J, Wang J, et al. Bone mineral accrual does not differ in HIV-infected children with and without lipodystrophy. XIV International Conference on AIDS. Barcelona, July 2002 [abstract ThPeB7233].
133. McGowan J, Cheng A, Coleman S, Johnson A, Genant H. Assessment of bone mineral density (BMD) in HIV-infected antiretroviral therapy naive subjects. Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [abstract 628].
134. Staszewski S, Gallant J, Pozniak A, Suleiman J. Favorable metabolic profile for tenofovir sioproxil fumarate (TDF) versus staduvidine (d4T) when used in combination iwth lamivudine and efavirenz in antiretroviral-naive patients: 96-week interim results. Second International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, July 2003 [abstract 562].
135. Lawal A, Engelson ES, Wang J, Heymsfield SB, Kotler DP. Equivalent osteopenia in HIV-infected individuals studied before and during the era of highly active antiretroviral therapy. AIDS 2001, 15:278-280.
136. Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 2003, 17:1917-1923.
137. Mondy K, Yarasheski K, Powderly WG, Whyte M, Claxton S, DeMarco D, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 2003, 36:482-490.
138. Leonard MB, Zemel BS. Current concepts in pediatric bone disease. Pediatr Clin North Am 2002, 49:143-173.
139. Katzman DK, Bachrach LK, Carter DR, Marcus R. Clinical and anthropometric correlates of bone mineral acquisition in healthy adolescent girls. J Clin Endocrinol Metab 1991, 73:1332-1339.
140. Prentice A, Parsons TJ, Cole TJ. Uncritical use of bone mineral density in absorptiometry may lead to size-related artifacts in the identification of bone mineral determinants. Am J Clin Nutr 1994, 60:837-842.
141. Glorieux FH, Travers R, Taylor A, Bowen JR, Rauch F, Norman M, et al. Normative data for iliac bone histomorphometry in growing children. Bone 2000, 26:103-109.
142. Calvo MS, Eyre DR, Gundberg CM. Molecular basis and clinical application of biological markers of bone turnover Endocr Rev 1996, 17:333-368.
143. Blumsohn A, Hannon RA, Wrate R, Barton J, al-Dehaimi AW, Colwell A, et al. Biochemical markers of bone turnover in girls during puberty. Clin Endocrinol (Oxf) 1994, 40:663-670.
144. Ramos J, Rojo P, Ruano C, Gonzalez-Tome M, Sanchez-Granados J, Vargas C, et al. Stability of osteopenia in HIV-infected children over time. Eleventh Conference on Retrovirus and Opportunistic Infections. San Francisco, February 2004 [abstract 745].
145. Mora S, Prinster C, Proverbio MC, Bellini A, de Poli SC, Weber G, et al. Urinary markers of bone turnover in healthy children and adolescents: age-related changes and effect of puberty. Calcif Tissue Int 1998, 63:369-374.
146. Tsekes G, Paraskeva D, Douskas G, Chini M, Mangafas N, Boboli M, et al. Bone loss is closely related to fat loss in HIV-infected patients receiving antiretroviral treatment. Tenth Conference on Retroviruses and Opportunistic Infections. Boston, February 2003 [abstract 764].
147. Lawal A, Engelson E, Wang J, Heymsefield S, Kotler D. Effect of oxandrolone upon bone mineral content in malnourished HIV+ patients. Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [abstract 636].
148. Lawal A, Engelson E, Wang J, Heymsfield SB, Kotler D. Effect of growth hormone on osteopenia in HIV+ patients. Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [abstract 635].
149. Mondy K, Powderly WG, Claxton S, Yarasheski KE, Stoneman JS, Hoffman M, et al. Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. Tenth Conference on Retroviruses and Opportunistic Infections 2003 [abstract 134].
150. Guaraldi G, Orlando G, Madeddu G, Vescini F, Ventura P, Campostrini S, et al. Alendronate reduces bone turnover in HIV-associated osteopenia and osteoporosis. Eleventh Conference on Retrovirus and Opportunistic Infections 2004 [abstract 742].
151. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004, 350:1189-1199.
152. Keruly JC, Chaisson RE, Moore RD. Increasing incidence of avascular necrosis of the hip in HIV-infected patients. J Acquir Immune Defic Syndr 2001, 28:101-102.
153. Glesby MJ, Hoover DR, Vaamonde CM. Osteonecrosis in patients infected with human immunodeficiency virus: a case-control study. J Infect Dis 2001, 184:519-523.
154. Brown P, Crane L. Avascular necrosis of bone in patients with human immunodeficiency virus infection: report of 6 cases and review of the literature. Clin Infect Dis 2001, 32:1221-1226.
155. Miller KD, Masur H, Jones EC, Joe GO, Rick ME, Kelly GG, et al. High prevalence of osteonecrosis of the femoral head in HIV-infected adults. Ann Intern Med 2002, 137:17-25.
156. Martin-Crespo R, Escorihuela A, Soleto J. Hip disease in AIDS children. VIII International Conference on AIDS. Amsterdam, July 1992 [abstract PuB7340].
157. Gaughan DM, Mofenson LM, Hughes MD, Seage GR, III, Ciupak GL, Oleske JM. Osteonecrosis of the hip (Legg-Calve-Perthes disease) in human immunodeficiency virus-infected children. Pediatrics 2002, 109:E74-E74.
158. Gerschenson M, Erhart SW, Paik CY, St Claire MC, Nagashima K, Skopets B, et al. Fetal mitochondrial heart and skeletal muscle damage in Erylhrocebus patas monkeys exposed in utero to 3′-azido-3′-deoxythymidine. AIDS Res Hum Retroviruses 2000, 16:635-644.
159. Ewings EL, Gerschenson M, St Claire MC, Nagashima K, Skopets B, Harbaugh SW, et al. Genotoxic and functional consequences of transplacental zidovudine exposure in fetal monkey brain mitochondria. J Acquir Immune Defic Syndr 2000, 24:100-105.
160. Blanche S, Tardieu M, Rustin P, Slama A, Barret B, Firtion G, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999, 354:1084-1089.
161. Barret B, Tardieu M, Rustin P, Lacroix C, Chabrol B, Desguerre I, et al. Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS 2003, 17:1769-1785.
162. No authors listed. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. J Acquir Immune Defic Syndr 2000, 25:261-268.
163. Gianquinto C, Rampon O, Torresan S, Ruga E, De Rossi A, Burlina A, et al. Lactic acid levels in infants exposed to ART during fetal life. Eleventh Conference on Retroviruses and Opportunistic Infections. San Francisco, February 2004 [abstract 941].
164. Alimenti A, Ogilvie G, Burdge D, Money D, Forbes J. Lactic acidemia in infants exposed to perinatal antiretroviral therapy. Ninth Conference on Retroviruses and Opportunistic Infections. Seattle, February 2002 [abstract 113].
165. Vigano A, Bianchi R, Schneider L, Cafarelli L, Tornhagi R, Pinti M, et al. Lack of hyperlactatemia and impaired mitochondrial DNA content in CD4+ cells of HIV-unifected infants exposed to perinatal antiretroviral therapy. Eleventh Conference on Retroviruses and Opportunistic Infections. San Francisco, February 2004 [abstract 942]2E
166. Chattha G, Arieff AI, Cummings C, Tierney LM, Jr. Lactic acidosis complicating the acquired immunodeficiency syndrome. Ann Intern Med 1993, 118:37-39.
167. Freiman JP, Helfert KE, Hamrell MR, Stein DS. Hepatomegaly with severe steatosis in HIV-seropositive patients. AIDS 1993, 7:379-385.
168. Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis 2000, 31:162-166.
169. Lenzo NP, Garas BA, French MA. Hepatic steatosis and lactic acidosis associated with stavudine treatment in an HIV patient: a case report. AIDS 1997, 11:1294-1296.
170. Sundar K, Suarez M, Banogon PE, Shapiro JM. Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: report of two patients and review of the literature. Crit Care Med 1997, 25:1425-1430.
171. Gerard Y, Maulin L, Yazdanpanah Y, De La Tribonniere X, Amiel C, Maurage CA, et al. Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy. AIDS 2000, 14:2723-2730.
172. Fortgang IS, Belitsos PC, Chaisson RE, Moore RD. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy. Am J Gastroenterol 1995, 90:1433-1436.
173. ter Hofstede HJ, de Marie S, Foudraine NA, Danner SA, Brinkman K. Clinical features and risk factors of lactic acidosis following long- term antiretroviral therapy: 4 fatal cases. Int J STD AIDS 2000, 11:611-616.
174. Lonergan JT, Havlir D, Barber E, Matthews WC. Incidence and outcome of hyperlactatemia associated with clinical manifestations in HIV-infected adults receiving NRTI-containg regimens. Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [abstract 624].
175. Chariot P, Drogou I, de Lacroix-Szmania I, Eliezer-Vanerot MC, Chazaud B, Lombes A, et al. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J Hepatol 1999, 30:156-160.
176. McComsey G, Hoppel C, Williams V, Lancaster T, Hernandez J, Ross L. Partial improvement of mitochondrial dysfunction 48 weeks after replacement of stavudine (d4T) with either abacavir (ABC) or zidovudine (ZDV). Eleventh Conference on Retroviruses and Opportunistic Infections. San Francisco, February 2004 [abstract 711].
177. Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA. Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Ann Intern Med 2000, 133:192-196.
178. Brinkman K, Troost N, Schrijnders L, Regez R, Treskes M, Vrouenraets S, et al. Usefulness of routine lactate measurement to prevent lactic acidosis: evaluation of a protocol. Ninth Conference on Retroviruses and Opportunistic Infections. Seattle, February 2002 [abstract 709].
179. John M, Moore CB, James IR, Nolan D, Upton RP, McKinnon EJ, et al. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001, 15:717-723.
180. McComsey C, Yau L,. Asymptomatic hyperlactatemia: predictive value, natural history and correlates. Antivir Ther 2004, 9:205-212.
181. Desai N, Mathur M, Weedon J. Lactate levels in children with HIV/AIDS on highly active antiretroviral therapy. AIDS 2003, 17:1565-1568.
182. Noguera A, Fortuny C, Sanchez E, Artuch R, Vilaseca MA, Munoz-Almagro C, et al. Hyperlactatemia in human immunodeficiency virus-infected children receiving antiretroviral treatment. Pediatr Infect Dis J 2003, 22:778-782.
183. Lonergan JT, Barber RE, Mathews WC. Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis. AIDS 2003, 17:2495-2499.
184. Lonergan JT, McComsey G, Fisher R, Shalit P, File T, Ward D, et al. Lack of recurrence of hyperlactatemia in HIV-infected patients switched from stavudine to abacavir or zidovudine. J Acquir Immune Defic Syndr 2004 in press.
185. Ribera E, Sauleda S, Paradineiro J, Tejada M, Aundreu AL, Marti R, et al. Increase in mitochondrial DNA in PBMCs and improvement of lipid profile and lactate levels in patients with lipoatrophy when stavudine is switched to tenofovir. Ninth European AIDS Conference. Warsaw, October 2003 [abstract F 15/4].
186. Nolan D, Hammond E, Martin A, Taylor L, Herrmann S, McKinnon E, et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003, 17:1329-1338.
187. Walker UA, Bickel M, Lutke Volksbeck SI, Ketelsen UP, Schofer H, Setzer B, et al. Evidence of nucleoside analogue reverse transcriptase inhibitor: associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. J Acquir Immune Defic Syndr 2002, 29:117-121.
188. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998, 281:1309-1312.
189. McComsey C, Paulsen D, Lonergan T, Milano D, Williams V, Pakes G, et al. Improvements in body fat, mitochondrial DNA levels and adipocyte apoptosis 48 weeks after replacement of stavudine with either abacavir or zidovudine appear independent of cellular cytokine mRNA levels. 41st Meeting of the Infectious Disease Society of America. San Diego, October 2003 [abstract 2003].
190. Maher B, Alfirevic A, Vilar FJ, Wilkins EG, Park BK, Pirmohamed M. TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. AIDS 2002, 16:2013-2018.
191. Domingo P, Veloso S, Montera F, Matias-Guiu X, Vialdes J, Aguilar C, et al. Serum levels of soluble tumor necrosis factor (TNF) receptors correlate with the degree of subcutaneous adipocyte apoptosis in HIV-infected patients with lipodystrophy. XIV AIDS International Conference. Barcelona, Spain 2002 [abstract WePeA5792].
192. de la Asuncion JG, del Olmo ML, Sastre J, Millan A, Pellin A, Pallardo FV, et al. AZT treatment induces molecular and ultrastructural oxidative damage to muscle mitochondria. Prevention by antioxidant vitamins. J Clin Invest 1998, 102:4-9.
193. Loffler M, Jockel J, Schuster G, Becker C. Dihydroorotate-ubiquinone oxidoreductase links mitochondria in the biosynthesis of pyrimidine nucleotides. Mol Cell Biochem 1997, 174:125-129.
194. Walker UA, Venhoff N, Koch EC, Olschewski M, Schneider J, Setzer B. Uridine abrogates mitochondrial toxicity related to nucleoside analogue reverse transcriptase inhibitors in HepG2 cells. Antivir Ther 2003, 8:463-470.
195. Caron M, Auclair M, Kornprobst M, Capeau J. Effects of nucleoside reverse transcriptase inhibitors on differentiation, response to insulin and apoptosis in cultured adipocytes. International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Paris, July 2003 [abstract 10].
196. Riddle TM, Kuhel DG, Woollett LA, Fichtenbaum CJ, Hui DY. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem 2001, 276:37514-37519.
197. Dubé M, Zackin R, Parker R, Yang Y, Grinspoon S, Tebas P, et al. Prospective study of glucose and lipid metabolism in antiretro-viral-naive subjects randomized to receive nelfinavir, efavirenz, or both zidovudine + lamivudine (ZDV + 3TC) or didanosine + stavudine: A5005s, a substudy of ACTG 384. Eleventh Conference on Retroviruses and Opportunistic Infections. San Francisco, February 2003 [abstract 74].